{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:03:24Z","timestamp":1788822204970,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010201","name":"U.S. Army Medical Research Institute of Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010201","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010203","name":"Walter Reed Army Institute of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-09-C-0049"],"award-info":[{"award-number":["HDTRA1-09-C-0049"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.01.047","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T17:28:40Z","timestamp":1644514120000},"page":"1864-1871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults"],"prefix":"10.1016","volume":"40","author":[{"given":"Kristopher M.","family":"Paolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Regules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shon A.","family":"Remich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin T.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadeidre N.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghariwayne A.","family":"Fornillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong Y.","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristan A.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mark Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Chichester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Streatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidadi","family":"Yusibov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.01.047_b0005","series-title":"Kaufmann AF, Anthrax","author":"Brachman","year":"1998"},{"key":"10.1016\/j.vaccine.2022.01.047_b0010","first-page":"277","article-title":"The aetiology of anthrax based on the ontogeny of the anthrax bacillus","volume":"2","author":"Koch","year":"1877","journal-title":"Beirt Biol Pflanz"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.047_b0015","first-page":"291","article-title":"A major epidemic of anthrax in Zimbabwe","volume":"28","author":"Davies","year":"1982","journal-title":"Cent Afr J Med"},{"issue":"3990","key":"10.1016\/j.vaccine.2022.01.047_b0020","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1126\/science.172.3990.1303","article-title":"Ecology of anthrax","volume":"172","author":"Van Ness","year":"1971","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.vaccine.2022.01.047_b0025","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense","volume":"281","author":"Inglesby","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.047_b0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Anthrax Bioterrorism Investigation, Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.01.047_b0035","first-page":"6","article-title":"An epidemic of inhalation anthrax: the first in the twentieth century. II. Epidemiology","volume":"72","author":"Brachman","year":"1960","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2022.01.047_b0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu Rev Biochem"},{"issue":"3-4","key":"10.1016\/j.vaccine.2022.01.047_b0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.047_b0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/IAI.74.1.394-398.2006","article-title":"Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits","volume":"74","author":"Weiss","year":"2006","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.047_b0055","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/iai.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs","volume":"65","author":"Little","year":"1997","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.047_b0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2672.1999.00898.x","article-title":"Immune correlates of protection against anthrax","volume":"87","author":"Fowler","year":"1999","journal-title":"J Appl Microbiol"},{"issue":"32","key":"10.1016\/j.vaccine.2022.01.047_b0065","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.047_b0070","unstructured":"FDA. BioThrax\u00ae (Anthrax Vaccine Adsorbed) Emergent BioSolutions; 2015."},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.047_b0075","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1467-7652.2010.00507.x","article-title":"Plant-made vaccines for humans and animals","volume":"8","author":"Rybicki","year":"2010","journal-title":"Plant Biotechnol J"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.047_b0080","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4161\/hv.3.4.4148","article-title":"Plants as alternative systems for production of vaccines","volume":"3","author":"Chichester","year":"2007","journal-title":"Hum Vaccin"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.047_b0085","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.biologicals.2008.09.001","article-title":"Plants as biofactories","volume":"36","author":"Mett","year":"2008","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.047_b0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1750-2659.2006.00005.x","article-title":"A launch vector for the production of vaccine antigens in plants","volume":"1","author":"Musiychuk","year":"2007","journal-title":"Influenza Other Respir Viruses"},{"issue":"16","key":"10.1016\/j.vaccine.2022.01.047_b0095","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/j.vaccine.2007.01.068","article-title":"Immunogenicity of a subunit vaccine against Bacillus anthracis","volume":"25","author":"Chichester","year":"2007","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2022.01.047_b0100","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1016\/j.vaccine.2007.01.017","article-title":"A plant-produced plague vaccine candidate confers protection to monkeys","volume":"25","author":"Mett","year":"2007","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2022.01.047_b0105","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2008.03.045","article-title":"Plant-expressed HA as a seasonal influenza vaccine candidate","volume":"26","author":"Shoji","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.047_b0110","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2008.11.108","article-title":"Plant-derived hemagglutinin protects ferrets against challenge infection with the A\/Indonesia\/05\/05 strain of avian influenza","volume":"27","author":"Shoji","year":"2009","journal-title":"Vaccine"},{"issue":"sup1","key":"10.1016\/j.vaccine.2022.01.047_b0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/hv.7.0.14561","article-title":"Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza","volume":"7","author":"Shoji","year":"2011","journal-title":"Hum Vaccin"},{"issue":"11","key":"10.1016\/j.vaccine.2022.01.047_b0120","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.3390\/v4113227","volume":"4","author":"Chichester","year":"2012","journal-title":"Viruses"},{"issue":"19","key":"10.1016\/j.vaccine.2022.01.047_b0125","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.vaccine.2013.10.017","article-title":"Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults","volume":"32","author":"Cummings","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.01.047_b0130","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4161\/hv.23233","article-title":"A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores","volume":"9","author":"Chichester","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2022.01.047_b0135","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.047_b0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"13","author":"Sever","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"13","key":"10.1016\/j.vaccine.2022.01.047_b0145","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"issue":"33\u201334","key":"10.1016\/j.vaccine.2022.01.047_b0150","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.047_b0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccin"},{"issue":"11","key":"10.1016\/j.vaccine.2022.01.047_b0160","doi-asserted-by":"crossref","first-page":"e13849","DOI":"10.1371\/journal.pone.0013849","article-title":"Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults","volume":"5","author":"Brown","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.047_b0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1128\/CVI.05556-11","article-title":"Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis","volume":"19","author":"Bellanti","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"29","key":"10.1016\/j.vaccine.2022.01.047_b0170","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2019.05.057","article-title":"Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study","volume":"37","author":"Kang","year":"2019","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2022.01.047_b0175","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1016\/j.vaccine.2021.08.075","article-title":"Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults","volume":"39","author":"Schneider","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.047_b0180","series-title":"The Anthrax Vaccine: Is It Safe? Does It Work?","article-title":"Institute of Medicine (US) Committee to Assess the Safety and Efficacy of the Anthrax Vaccine","year":"2002"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:13Z","timestamp":1759403413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22000937"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}